Q BioMed, a biomedical acceleration and development company, has signed an exclusive option agreement with Washington University in St Louis for a novel companion biomarker for monitoring glaucoma. more


The latest report from data and analytics company, GlobalData, has revealed that the glaucoma market is expected to grow to $3.8 billion in 2026 as a result of the launch of pipeline products. more


A new drug application (NDA) for VYZULTA — a prostaglandin analogue indicated for the reduction of intraocular pressure (IOP) — has been approved by the US Food and Drug Administration (FDA). more


A contact lens designed to deliver medication gradually to the eye may improve outcomes for patients who struggle with imprecise, difficult to self-administer eye drops more